Phase IIb trial of EVT-201 for treatment of insomnia in China

Trial Profile

Phase IIb trial of EVT-201 for treatment of insomnia in China

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2015

At a glance

  • Drugs EVT 201 (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Zhejiang Jingxin Pharmaceutical
  • Most Recent Events

    • 14 Mar 2015 Status changed from not yet recruiting to recruiting in 2014, according to an Evotec media release.
    • 12 Aug 2014 According to an Evotec media release, JingXin Pharmaceutical Co., Ltd, received approval from the China State Food and Drug Administration (SFDA) for this study and plans to start in the second half of 2014.
    • 09 Aug 2013 According to an Evotec media release, Zhejiang JingXin Pharmaceutical was granted permission in April 2013 by the Chinese Center of Drug Evaluation (CDE) to commence clinical trials of EVT 201.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top